神经节苷脂联合左乙拉西坦治疗儿童病毒性脑炎继发癫痫的有效性及安全性分析

doi:10.3969/j.issn.1671-7171.2024.09.031

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1190 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy and safety of ganglioside combined with levetiracetam in the treatment of secondary epilepsy in children with viral encephalitis. 【Methods】A total of 71 children with secondary epilepsy caused by viral encephalitis admitted to our hospital from January 2021 to January 2023 were selected. According to the treatment method, they were divided into the control group (n=35, conventional treatment + levetiracetam) and the observation group (n=36, combined with ganglioside on the basis of treatment in the control group). The clinical efficacy, serum indicators [neuron specific enolase (NSE), serum interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α)], cerebrospinal fluid indicators [pulmonary surfactant protein D (SP-D), galectin-9 (Gal-9)], as well as the frequency and safety of epileptic seizures after treatment were compared between two groups of children. 【Result】After treatment, the clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of serum NSE, IL-6, TNF-α, and cerebrospinal fluid Gal-9 in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05); The levels of SP-D in the cerebrospinal fluid of both groups were higher than before treatment, and the observation group was higher than the control group (P<0.05). After discharge, the observation group showed better results than the control group in terms of no seizures or reduced seizure frequency (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The clinical effect of ganglioside combined with levetiracetam in the treatment of secondary epilepsy in children with viral encephalitis is good, improving their immune response, effectively reducing the frequency of seizures, and ensuring good safety.

Key words： Encephalitis, Viral Epilepsy Gangliosides/TU Levetiracetam/TU Treatment Outcome

Received: 14 October 2023

PACS:

R725.123

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Chuanping
	LI Huali

Cite this article:

LI Chuanping,LI Huali. Efficacy and Safety Analysis of Ganglioside Combined with Levetiracetam in the Treatment of Secondary Epilepsy in Children with Viral Encephalitis[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1392-1394.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.09.031 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I9/1392

[1] 赵婷婷. 白虎汤加味联合神经节苷脂治疗小儿病毒性脑炎的效果[J].临床合理用药杂志,2021,14(5):131-133.
[2] 陈孔博,邵元.更昔洛韦联合神经节苷脂治疗病毒性脑炎疗效及对患儿血清和脑脊液指标的影响[J].陕西医学杂志,2019,48(4):505-507.
[3] 李超,潜丽俊,应灵晶.神经节苷脂联合干扰素治疗小儿病毒性脑炎的疗效观察[J].中国妇幼保健,2019,34(12):2749.
[4] 李小玉,章鹏,何小庆. 左乙拉西坦联合苯巴比妥和卡马西平治疗难治性部分性癫痫临床研究[J].医学临床研究,2020,37(6):943-946.
[5] 黄志华. 儿童病毒性脑炎的诊断与治疗[J].中国临床医生杂志, 2004, 32(5):3-5.
[6] 中国抗癫痫协会. 临床诊疗指南:癫痫病分册(2015修订版)[M]. 北京:人民卫生出版社, 2015:132-135.
[7] 方红军,胡文静,江志,等. 阿昔洛韦联合奥卡西平对单纯性疱疹病毒性脑炎伴癫痫患儿的疗效及安全性[J].实用药物与临床,2020,23(4):345-349.
[8] 张天照.左乙拉西坦和卡马西平治疗癫痫的临床研究[J].中国临床药理学杂志,2021,37(8):962-965.
[9] 米艺果,马阳.神经节苷脂辅助高压氧治疗小儿病毒性脑炎的临床研究[J].青岛医药卫生,2024,56(3):219-223.
[10] 冯战超,马艳.更昔洛韦联合神经节苷脂对小儿病毒性脑炎血清NSE及炎性因子的影响[J].国际医药卫生导报,2018,24(17):2646-2648.
[11] 冯刚.菖蒲郁金汤辅助治疗重症病毒性脑炎对神经功能、S100B、NSE的影响[J].中华中医药学刊,2019,37(7):1744.
[12] 姜雪莹,任丹,赵荣香,等. 血清sVCAM-1、NSE与Gal-9联合检测病毒性脑炎患儿病情程度变化的判定价值[J].标记免疫分析与临床,2019,26(4):679-682.
[13] 李俊华. 白虎汤加味联合神经节苷脂对小儿病毒性脑炎外周血细胞因子指标及脑脊液中 SP-D和Gal-9表达的影响[J].中医药信息,2019,36(2):22-26.